CDSCO Approves India's First Dengue Vaccine: A Milestone in Public Health
GS2GS3
The Central Drugs Standard Control Organisation (CDSCO) has granted approval for the Qdenga dengue vaccine, a significant step in combating the four distinct serotypes of the virus as it spreads into rural and semi-urban regions.
The Central Drugs Standard Control Organisation (CDSCO) has officially approved the Qdenga dengue vaccine, marking a landmark achievement in India’s public health landscape. Dengue, a vector-borne disease transmitted by Aedes mosquitoes, has historically posed a significant challenge to India’s healthcare system, often overwhelming urban infrastructure during peak monsoon seasons. The approval of this vaccine is particularly timely as the disease footprint expands from traditional urban centers into semi-urban and rural areas, likely driven by changing climatic patterns and rapid, unplanned urbanization.
Qdenga is designed to provide protection against all four distinct dengue serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). This multi-valent approach is critical because secondary infections with a different serotype are often associated with more severe clinical outcomes, such as Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS). By mitigating the risk of severe disease, the vaccine is expected to reduce the burden on tertiary care hospitals and lower the economic impact of the disease on households.
Continue reading — free with login
JeetoBharat publishes daily UPSC current affairs mapped to the Mains syllabus. Log in to read full articles.
Log in to read full articleNo credit card required. Free registered users get unlimited access.
This article was curated using AI. While we strive for accuracy, please verify critical facts from official sources.